History
Carboplatin was discovered at Michigan State University, and developed at the Institute of Cancer Research in London. Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available. Research
Carboplatin has also been used for adjuvant therapy of stage 1 seminomatous testicular cancer. Research has indicated that it is not less effective than adjuvant radiotherapy for this treatment, while having fewer side effects. This has led to carboplatin based adjuvant therapy being generally preferred over adjuvant radiotherapy in clinical practice.Carboplatin combined with hexadecyl chain and polyethylene glycol appears to have increased liposolubility and PEGylation. This is useful in chemotherapy, specifically non-small cell lung cancer. See also
Cisplatin
Dicycloplatin

References
Additional references
External links
Creatinine Clearence [sic] Calculator
"Carboplatin". Drug Information Portal. U.S. National Library of Medicine.
However, transdermal selegiline, known by its trade name Emsam, is still contraindicated. Transdermal selegiline results in higher plasma levels at which it behaves like a non-selective MAO inhibitor. Concominant use of entacapone, a component of carbidopa/levodopa/entacapone, with MAO inhibitors may increase toxicity of MAO inhibitors. Levodopa, also a component of carbidopa/levodopa/entacapone, in combination with MAO inhibitors may result in hypertensive reactions. Mechanism of action
Levodopa is the immediate precursor to dopamine. Entacapone is a selective, reversible catechol-O-methyltransferase (COMT) inhibitor that prevents the degradation of levodopa. Entacapone does not cross the blood–brain barrier. Carbidopa is a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor. Carbidopa, which also does not cross the blood–brain barrier, is combined with levodopa to prevent its conversion to dopamine in the periphery. Society and culture
Extension
As of 2010, applications for extending the indication of carbidopa/levodopa/entacapone to people requiring initiation of levodopa therapy have been under review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), based on the favorable results from FIRST-STEP, a study conducted in North America and Europe by Novartis from 2005, to 2007 (see below). References
External links
"Carbidopa mixture with entacapone and levodopa". Drug Information Portal. U.S. National Library of Medicine. "Entacapone/Carbidopa/Levodopa (marketed as Stalevo) Information". U.S. Food and Drug Administration (FDA). 6 April 2017.